Similar to OC, endometrial malignancies tend to carry favorable prognoses when early detection is realized. Diagnosis at a later stage, however, typically coincides with a poor prognosis and a ...
Recently, a Risk of Ovarian Malignancy Algorithm (ROMA) utilising human epididymis secretory protein 4 (HE4) and CA125 successfully classified patients as presenting a high or low risk for epithelial ...
Ovarian cancer remains a significant challenge in women's health, with high mortality rates due to late-stage diagnosis. This webinar aims to provide healthcare professionals with an in-depth ...
Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...
Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC). Is it time to change the primary endpoint in clinical trials in ...
ABBOTT PARK, Ill., June 3 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) has cleared a new diagnostic test to monitor ovarian cancer, a disease ...
At the recent ASCO meeting, researchers from the University of Rochester reported preclinical data for on a new small-molecule inhibitor of WAP four-disulfide core domain protein 2 (HE4) – UR-238 – ...
Ovarian cancer is a relatively manageable malignancy when diagnosed at an early stage, but late-stage detection almost always translates into a poor prognosis. Researchers have been vigorously working ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback